The IRMA Community
Newsletters
Research IRM
Click a keyword to search titles using our InfoSci-OnDemand powered search:
|
Resistance Phenotypes and Surveillance
|
Author(s): Shahrukh Khan (Center for Disease Dynamics, Economics, and Policy, India)and Jyoti Joshi (Center for Disease Dynamics, Economics, and Policy, India & Amity Institute of Public Health, Amity University, India)
Copyright: 2021
Pages: 15
Source title:
Strategies to Overcome Superbug Invasions: Emerging Research and Opportunities
Source Author(s)/Editor(s): Dimple Sethi Chopra (Punjabi University, India)and Ankur Kaul (Institute of Nuclear Medicine and Allied Sciences, India)
DOI: 10.4018/978-1-7998-0307-2.ch001
Purchase
|
Abstract
The emergence of drug resistance complicates surveillance and treatment of antimicrobial phenotypes. For example, the rise of Methicillin-resistant Staphylococcus aureus and carbapenem-resistant Enterobacteriaceae influence delivery of care. Moreover, a lack of surveillance programs in most of the developing world exacerbates the problem of MDR. Existing studies in humans are mostly retrospective single-center surveillance-based studies that look at the molecular makeup and prevalence of phenotypic resistance for several pathogens. Very few studies examined infection prevention measures or antimicrobial stewardship activities, and of those that did, none of them were multicenter. The aim of this chapter is to explore prevalent phenotypes in clinical settings and antimicrobial resistance (AMR) surveillance programs throughout the world.
Related Content
Sharon L. Burton.
© 2024.
25 pages.
|
Laura Ann Jones, Ian McAndrew.
© 2024.
24 pages.
|
Olayinka Creighton-Randall.
© 2024.
14 pages.
|
Stacey L. Morin.
© 2024.
11 pages.
|
N. Nagashri, L. Archana, Ramya Raghavan.
© 2024.
22 pages.
|
Esther Gani, Foluso Ayeni, Victor Mbarika, Abdullahi I. Musa, Oneurine Ngwa.
© 2024.
25 pages.
|
Sia Gholami, Marwan Omar.
© 2024.
18 pages.
|
|
|